AbbVie says strong results lessen need for big deal

"The underlying growth prospects of AbbVie don't require us to do a deal of that size," AbbVie Chief Executive Richard Gonzalez said in conference call, but added the company was keen on smaller acquisitions, particularly of treatments involving rare diseases, cancer and hepatology. Excluding special items, including charges for the attempted Shire deal, AbbVie earned 89 cents per share. Analysts on average expected 77 cents, according to Thomson Reuters I/B/E/S.

via Business News http://ift.tt/1u1nqWV